Equity-based transaction with Winklevoss Capital activates 4.2 GSol/s of live, U.S.-based hashrate; approximately 18% of the Zcash network; Industry veteran Kevin Zhang joins as Head of Mining

CAMBRIDGE, Mass., Aug. 18, 2026 /PRNewswire/ — Cypherpunk Technologies Inc. (Nasdaq: CYPH) (“Cypherpunk”) today announced the launch of Cypherpunk Mining, which is now the largest Zcash mining fleet in the world, through a $33.33 million equity-based transaction with Winklevoss Capital. The fleet is online today, with approximately 4.2 GSol/s of Equihash hashrate deployed across the United States, which currently represents approximately 18% of the total Zcash network.

“Up until now, investors have had limited options for Zcash mining exposure. With the acquisition of this mining fleet, Cypherpunk changes that,” said Cameron and Tyler Winklevoss. 

With the launch, Cypherpunk now offers public market investors exposure to both Zcash mining and treasury upside and continues Cypherpunk’s evolution into a diversified privacy technology company.

“Following the expansion of our ZEC treasury and investment in ZODL, Zcash mining is the next piece of the constellation of privacy technologies we’re assembling,” said Will McEvoy, Chief Investment Officer of Cypherpunk. “The Zcash flow from Cypherpunk Mining provides financial and operational flexibility to fund future growth, the acquisition of additional ZEC, and new privacy-preserving technology investments.”

Through this transaction with Winklevoss Capital, Cypherpunk Mining immediately becomes the Zcash network’s largest active fleet, currently deployed across U.S.-based facilities with industry-leading uptimes and hosting rates, accessing an addressable market valued at over $250 million per year at current ZEC prices.

Strengthening Cypherpunk’s Treasury and the Zcash Network

Cypherpunk Mining now stands alongside Cypherpunk’s ZEC treasury and its privacy investment strategy anchored by ZODL, the most widely used Zcash wallet. As approximately 43,800 ZEC are awarded to miners each month, mining meaningfully accelerates the company’s path to its target of holding 5% of ZEC supply, at production costs that are significantly lower than spot price. 

As the largest corporate holder of ZEC, currently with 323,394.38 ZEC representing approximately 1.92% of the circulating supply, Cypherpunk’s incentives are aligned with the network’s. The additional mining hashrate and decentralization strengthens Zcash network security, and a more secure Zcash makes Cypherpunk’s treasury more valuable. Cypherpunk intends to serve as a bridge between Zcash miners, developers, and the broader ecosystem.

Kevin Zhang Joins as Head of Mining

Kevin Zhang joins Cypherpunk as Head of Mining, bringing more than a decade of experience at the front lines of Bitcoin and Zcash. Zhang began mining Bitcoin in 2014 and Zcash in 2016, built several of the largest Bitcoin mining facilities in North America, and in 2019 led the first power plant conversion to Bitcoin mining on the continent. At Foundry, he built the largest Bitcoin mining pool in the world and deployed one of the largest crypto mining operations.

“Approximately 1,440 ZEC is awarded to miners each day, making Zcash mining highly profitable. Even if the Zcash network hashrate increases significantly, Zcash mining still out-earns AI colocation and Bitcoin mining at today’s ZEC prices,” said Kevin Zhang, Head of Mining at Cypherpunk. “The opportunity in Zcash mining shows a striking similarity to Bitcoin mining in 2016 and provides exciting growth potential for Cypherpunk.”

Description of the Transaction

Cypherpunk and Cypherpunk Mining LLC (“Cypherpunk Mining”) entered into an Asset Purchase Agreement with Moria Mining LLC and Winklevoss Treasury Investments, LLC pursuant to which Cypherpunk Mining acquired the latest generation Z15 Pro machines with an aggregate hashpower of approximately 4.2 GSol/s along with their related hosting agreements. The aggregate purchase price of $33.33 million was paid for by the issuance of a pre-funded warrant to Winklevoss Treasury Investments, LLC to purchase 43,290,042 shares of common stock of Cypherpunk at an exercise price of $0.001 per share, reflecting a Cypherpunk common stock purchase price of $0.77 per share.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov. 

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the Company’s ZEC mining operations, the hashpower represented by the acquired Z15 Pro machines, the potential Zcash flow or profitability of the Company’s mining operations, the comparative economics or profitability of Zcash mining relative to other digital infrastructure or mining activities, the future hashrate of the Zcash Network, the value of the Company’s ZEC holdings, the Company’s target percentage ownership of the ZEC supply, the expected future market, price, and liquidity of ZEC, the Company’s expected use of Zcash flow or other capital generated by its mining operations, the potential value of the Company’s investment in Zcash Open Development Labs (“ZODL”), the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the Company’s strategy include, among others: (a) risks relating to the Company’s operations and business, including the performance of the Company’s Zcash mining machines and highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings, and reduced net income or increased net loss; (c) the risk that material changes in the hashrate of the Zcash Network, such as increases in hashrate, will result in significant changes to the Company’s financial statements, such as reduced revenue, reduced gross margins, and reduced net income or increased net loss; (d) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (e) the risk that the Company will fail to realize the anticipated benefits of the ZEC mining operation or digital asset treasury strategy; (f) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (g) changes in business, market, financial, political and regulatory conditions; (h) risks related to increased competition in the industries in which the Company does and will operate; (i) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (j) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; (k) risks related to the Company’s dependence on third-party hosting facilities and service providers for its mining operations; and (l) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cypherpunk-technologies-launches-worlds-largest-zcash-mining-fleet-302853518.html

SOURCE Cypherpunk Technologies Inc.

Authorization granted within the school’s first year of operation at the Oakdale campus

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Harrow International School New York has been authorized by the International Baccalaureate Organization as an IB World School for the Middle Years Programme. The authorization was granted on June 24, 2026 and applies to Grades 6 through 10 at the school’s 170-acre waterfront campus in Oakdale, New York.

“We are proud to be authorized as an IB World School. As an IB candidate school, we have taught within the Middle Years Programme framework since we opened in September 2025, and achieving full authorization in under a year tells us our academic program met the standard the IB expects. The families who joined us in our founding year did so on the strength of a promise, and this is one of the ways we show them the promise is being kept,” said Matthew S. Sipple, Principal of Harrow International School New York. 

Authorization as an IB World School follows a multi-stage review conducted by the International Baccalaureate Organization. The process confirms that a school is prepared to offer an IB programme with fidelity to the IB’s programme standards and practices, rules and regulations. Only schools authorized as IB World Schools may offer an IB programme, and every five years after authorization a school participates in a programme evaluation.

Harrow New York received its Provisional Charter from the New York State Education Department in January 2025 and opened in September 2025 with Grades 6 through 9. Authorization as an IB World School for the Middle Years Programme was granted in June, within the school’s first year of operation.

The school is also a candidate for the IB Diploma Programme, authorization expected in December, which will be offered in grades 11 and 12 starting in the fall of 2027. Candidate status gives no guarantee that authorization will be granted. The school enrolls students in Grades 6 through 10 in the 2026-27 academic year and adds one grade level each year, reaching Grade 12 in the 2028-29 academic year.

The IB Middle Years Programme is designed for students aged 11 to 16 and emphasizes inquiry-based learning across eight subject groups, alongside a personal project completed in the final year of the programme. Students at Harrow New York follow the Middle Years Programme framework alongside the school’s house system, extended day, and co-curricular program. Harrow International School New York has taught within the Middle Years Programme framework since it opened in September 2025. Every student at Harrow International School New York has a Head of House and a Personal Tutor.

“The Middle Years Programme asks a student to stay with a question long enough to discover it is harder than they first thought. That takes time in a lesson, and it takes teachers willing to follow where the thinking goes. Our students have worked this way since our first term, and authorization confirms that what we have built here is the programme as the IB intends it,” said Mark Frankel, Vice-Principal and Director of Studies at Harrow International School New York.

The school offers day placement, five-day boarding, and seven-day boarding. Approximately 60 percent of current students board and 40 percent attend as day students. Five-day boarding students live on campus Monday through Friday and return home for weekends. The Oakdale station of the Long Island Railroad is a short distance from the campus, connecting the school to NYC and the Hamptons.

Harrow International School New York is currently accepting applications for the 2026-27 academic year in Grades 6 through 10, for day placement, five-day boarding and seven-day boarding. Admission is on a rolling basis, and families are invited to visit the Oakdale campus year-round. 

Harrow New York is a day and boarding school for Grades 6 through 12, located approximately one hour east of Manhattan on Long Island’s South Shore. The school is the first in the United States to carry the name of Harrow School, which was founded in London in 1572. 

Frequently Asked Questions

Is Harrow New York an IB World School?
Yes. Harrow International School New York, known locally as Harrow New York, is authorized by the International Baccalaureate Organization as an IB World School for the Middle Years Programme, effective June 24, 2026.

Which IB programme does Harrow NY teach?
Harrow International School New York is authorized to teach the IB Middle Years Programme. The authorization applies to Grades 6 through 10.

Will Harrow New York offer the IB Diploma Programme?
Harrow International School New York intends to seek authorization for the IB Diploma Programme for Grades 11 and 12.

Are scholarships or financial aid available at Harrow New York?
Yes. All students joining Harrow International School New York for the 2026-27 academic year automatically receive the Pioneer’s Scholarship, with no separate application required. Harrow International School New York also offers need-based financial aid to qualifying families, for both day placement and boarding, considered alongside applications for admission.

How does the IB Middle Years Programme prepare students for university?
The IB Middle Years Programme is designed for students aged 11 to 16 and emphasizes inquiry-based learning, research skills and independent study across eight subject groups. Harrow International School New York intends to seek authorization for the IB Diploma Programme for Grades 11 and 12. The IB Diploma Programme is widely recognized by universities in the United States and internationally. Candidate status gives no guarantee that authorization will be granted.

Where is Harrow New York located?
Harrow International School New York is located at 500 Montauk Highway, Oakdale, New York 11769, on a 170-acre campus on the Great South Bay, approximately one hour east of Manhattan, NYC and one hour west of the Hamptons. The campus is served by the Oakdale station of the Long Island Railroad and is within easy reach of Long Island MacArthur, John F. Kennedy International and LaGuardia airports.

How far is Harrow New York from Manhattan?
Harrow International School New York is approximately one hour east of Manhattan by car, and the Oakdale station of the Long Island Railroad is a short distance from the campus.

What grade levels does Harrow New York serve?
Harrow International School New York serves Grades 6 through 10 in the 2026-27 academic year and adds one grade level each year, reaching Grade 12 in 2028-29.

Is Harrow New York the same as Harrow School in London?
Harrow International School New York is a separate school in Oakdale, New York, and is the first school in the United States to carry the Harrow name. Harrow School was founded in London in 1572.

About Harrow International School New York

Harrow International School New York is a day and boarding school for Grades 6 through 12 located at 500 Montauk Highway, Oakdale, New York, on a 170-acre waterfront campus one hour east of Manhattan and one hour west of the Hamptons. The school received its Provisional Charter from the New York State Education Department in January 2025 and opened in September 2025. It is the first school in the United States to carry the name of Harrow School, founded in London in 1572. Harrow International School New York is an authorized International Baccalaureate World School* for the Middle Years Programme. Every student has a Head of House and a Personal Tutor. The school offers day placement, five-day boarding, and seven-day boarding. More information is available at harrownewyork.com.

*Only schools authorized by the IB Organization can offer any of its four academic programmes: the Primary Years Programme (PYP), the Middle Years Programme (MYP), the Diploma Programme (DP), or the Career-related Programme (CP). Candidate status gives no guarantee that authorization will be granted. For further information about the IB and its programmes, visit ibo.org.

Media Contact
Ryan Allison
Director of Marketing and Communications
Harrow International School New York
ryan.allison@harrownewyork.com | 631-869-1572

View original content to download multimedia:https://www.prnewswire.com/news-releases/harrow-international-school-new-york-authorized-as-an-ib-world-school-302853412.html

SOURCE Harrow International School New York

Seasoned drug development leader to drive clinical development of small molecule IRF5 inhibitor, HST-2011, nominated as Development Candidate for lupus and other autoimmune diseases

BOSTON, Aug. 18, 2026 /PRNewswire/ — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the appointment of Niti Goel, M.D., as Chief Medical Officer.

“Niti has deep, multi-faceted expertise in immunology clinical development, and this expertise will be vital as we prepare to advance our IRF5 inhibitor, HST-2011, into the clinic for lupus and other autoimmune diseases,” said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Therapeutics. “Her track record of guiding innovative immunology programs from the earliest stages of clinical development through drug approval, together with her physician-scientist perspective and commitment to patients, will be invaluable as we work to advance HST-2011 through the clinic and translate our Smart AllosteryTM platform into meaningful new medicines.”

Niti Goel, M.D., is a board-certified rheumatologist and physician-scientist with over 25 years of notable contributions across global pharmaceutical and biotechnology companies, contract research organizations, academic medicine, and strategy consulting. Prior to joining HotSpot, she held senior leadership roles at TrialSpark (now Formation Bio), Abcuro, Kezar Life Sciences, and IQVIA, as well as various roles at Array BioPharma, UCB Pharma, and Procter & Gamble Pharmaceuticals. She is currently an Adjunct Assistant Professor at Duke University School of Medicine, precepting trainees in the rheumatology clinic at the Durham Veterans Administration Hospital. She is an author of numerous peer-reviewed scientific publications. Dr. Goel graduated summa cum laude with her M.D. degree from Jefferson Medical College of Thomas Jefferson University and received her bachelor’s degree from Pennsylvania State University; she completed her internal medicine and rheumatology training at Duke University Medical Center.

“I am excited to join HotSpot at such an important stage in the Company’s evolution, with their small molecule IRF5 inhibitor, HST‑2011, poised to enter the clinic as a potential once-daily oral option for people living with lupus and other autoimmune diseases,” said Dr. Goel. “HotSpot’s platform has the potential to unlock important biology across a broad range of immunology targets, and I look forward to working with the team to advance HST-2011 and the broader pipeline for and with patients who need new treatment options.”

HotSpot also announced it has nominated HST-2011, a small molecule interferon regulatory factor 5 (IRF5) inhibitor, as the Development Candidate for its IRF5 inhibitor program. IRF5 is a transcription factor involved in a diverse range of biological activities in which it functions as a master regulator of innate immunity. Genome-wide association studies have established compelling evidence as to the involvement of IRF5 in multiple inflammatory and immune system disorders, including systemic lupus erythematosus (SLE), Sjögren’s disease, rheumatoid arthritis, systemic sclerosis, and myositis. Leveraging the Company’s proprietary Smart Allostery™ platform, HotSpot has developed HST-2011 as a potent and selective small molecule IRF5 inhibitor that effectively drugs the target.

About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called “natural hotspots.” These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company’s proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots, as well as tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases. To learn more, visit www.hotspotthera.com.

HotSpot Investor & Media Contact:
Natalie Wildenradt
nwildenradt@hotspotthera.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-appoints-niti-goel-md-as-chief-medical-officer-302853577.html

SOURCE HotSpot Therapeutics